Cover Image

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

Bevacizumab‐pemetrexed/cisplatin (BEV‐PEM/CIS) is a first‐line therapeutic for advanced nonsquamous non‐small cell lung cancer. Bevacizumab potentiates PEM/CIS cytotoxicity by inducing transient tumor vasculature normalization. BEV‐PEM/CIS has a narrow therapeutic window. Therefore, it is an attract...

Full description

Saved in:

Bibliographic Details
Main Authors:	Benjamin K. Schneider (Author), Arnaud Boyer (Author), Joseph Ciccolini (Author), Fabrice Barlesi (Author), Kenneth Wang (Author), Sebastien Benzekry (Author), Jonathan P. Mochel (Author)
Format:	Book
Published:	Wiley, 2019-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Mechanistic models for hematological toxicities: Small is beautiful
by: Laure Deyme, et al.
Published: (2021)

Anaphylactic Reaction to Pemetrexed: A Case Report
by: Heloise Capelle, et al.
Published: (2014)

Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell
by: Jonathan González García, et al.
Published: (2017)

Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma
by: Ranjit K Goudar
Published: (2008)

OUR EXPERIENCE WITH PEMETREXED/ CISPLATIN AS FIRST LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON- SQUAMOUS NON- SMALL CELL LUNG CANCER
by: Deyan N. Davidov
Published: (2013)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
by: Xin Li, et al.
Published: (2021)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
by: Chun-Hua Zhou, et al.
Published: (2021)

Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy
by: Derek B. Oien, et al.
Published: (2018)

Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy
by: Guillaume Sicard, et al.
Published: (2020)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
by: Zhong AY, et al.
Published: (2015)

Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC)
by: Enriqueta Felip, et al.
Published: (2008)

Pemetrexed as first-line therapy for non-squamous non-small cell lung cancer
by: Serena Ricciardi, et al.
Published: (2009)

Edema of the face and extremities secondary to pemetrexed
by: Thomas Doyle, MS, et al.
Published: (2023)

Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
by: Peng Cao, et al.
Published: (2022)

Planning and Scheduling Optimization
Published: (2021)

Pemetrexed-induced eccrine squamous syringometaplasia manifesting as pseudocellulitis (in a patient with non-small cell lung cancer)
by: Adinia Santosa, MD, et al.
Published: (2017)

miR-6077 promotes cisplatin/pemetrexed resistance in lung adenocarcinoma via CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways
by: Guoshu Bi, et al.
Published: (2022)

Machine-Learning Exploration of Exposure-Effect Relationships of Cisplatin in Head and Neck Cancer Patients
by: Céleste Cauvin, et al.
Published: (2022)

Anti-Angiogenic Effect of Orally Available Pemetrexed for Metronomic Chemotherapy
by: Ruby Maharjan, et al.
Published: (2019)

Optimizing dose-schedule regimens with bayesian adaptive designs: opportunities and challenges
by: Xin Chen, et al.
Published: (2023)

Alvopem® (pemetrexed) safety assessment in patients with non-small cell lung cancer or malignant pleural mesothelioma: a post-marketing surveillance
by: Sharareh Seifi, et al.
Published: (2023)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
by: Chien C-R, et al.
Published: (2012)

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
by: Yuzo Sato, et al.
Published: (2021)

The role of pemetrexed in recurrent epithelial ovarian cancer: a scoping review
by: Michael Roche, et al.
Published: (2018)

Bevacizumab for glioblastoma
by: Narita Y
Published: (2015)

Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
by: Steven F Powell, et al.
Published: (2009)

Validation of a novel causality assessment scale for adverse events in non-small cell lung carcinoma patients treated with platinum and pemetrexed doublet chemotherapy
by: Jyoti Bhagatram Sharma, et al.
Published: (2021)

PHARMACOECONOMIC EVALUATION OF THE MEDICINAL PRODUCTS ERLOTINIB, DOCETAXEL, PEMETREXED AND GEFITINIB IN THE SECOND-LINE TREATMENT OF LOCALLY-ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
by: A. U. Kulikov
Published: (2015)

Engagement of hospital pharmacists and technicians to optimize staffing schedules
by: Jessica Wright, et al.
Published: (2021)

Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer
by: Leda Severi, et al.
Published: (2018)

Effect of Formulation Factors and Oxygen Levels on the Stability of Aqueous Injectable Solution Containing Pemetrexed
by: Dong Han Won, et al.
Published: (2020)

HPV vaccination programs in LMIC: is it time to optimize schedules and recommendations?
by: Luisa Lina Villa, et al.
Published: (2023)

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
by: Lister J, et al.
Published: (2012)

Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients
by: Zulfan Zazuli, et al.
Published: (2020)

Methylphenidate Dosing Schedules
by: J Gordon Millichap
Published: (1996)

Efficacy and safety evaluations of anlotinib in patients with advanced non-small cell lung cancer treated with bevacizumab
by: Fenge Jiang, et al.
Published: (2022)

Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity
by: Ruby Maharjan, et al.
Published: (2021)

Preparation, Characterization, and In Vivo Evaluation of an Oral Multiple Nanoemulsive System for Co-Delivery of Pemetrexed and Quercetin
by: Rudra Pangeni, et al.
Published: (2018)

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab
by: Di Cao, et al.
Published: (2023)

Bevacizumab-Induced Geographic Tongue
by: Marta Martinez-Garcia, et al.
Published: (2021)